Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of ALXN1920 in Healthy Adults
NCT05751642Phase 1Completed
- Sponsor
- Alexion Pharmaceuticals
- Start
- Apr 2023
- Primary completion
- Dec 2023
- Modality
- Fc-Fusion Proteins
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of ALXN-1920 in primary membranous nephropathy (PMN) (7 arms), sponsored by Alexion Pharmaceuticals. Primary endpoint: Number of participants with Adverse events (AEs). Started Apr 2023; status: completed.
02
Drugs
ALXN-1920
03
Conditions
primary membranous nephropathy (PMN)
Beyond the preview
Go deeper on NCT05751642.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05751642.